imatinib (YD312) / YD Global - LARVOL DELTA

Sylvester Experts Explain the Most Promising Advances in Cancer Research and Treatment Presented at ASCO 2022 (University of Miami) - "'There was a lot of neoadjuvant therapy research presented at ASCO this year' in melanoma, said Jose Lutzky...Participants with pathologic complete response or near-complete response were spared total lymph node resection. 'Index node status does in fact predict what you will find in the rest of the nodal basin,' Dr. Lutzky said."

Media quote

In PE, cancer patients suffer from the lack of medicine provided by the Ministry of Health [Google translation] - "The damage to the health of those who had their treatment interrupted is classified as huge by the oncologist-hematologist Breno Gusmao...'Patients who do not receive imatinib and continue to do so are at risk of relapse. It could be that she is mild or aggressive, we cannot guarantee. The risk we take in leaving the patient untreated is very serious and unnecessary,' he says. A severe relapse could generate a blast crisis or an acute leukemia crisis, requiring the patient to undergo chemotherapy and a bone marrow transplant."

Media quote

Advances in Treatment of Previously Treated Ph+ Chronic Myeloid Leukemia - Episode 11: An Overview of CML Treatment Toxicities (OncLive) - "Jorge E. Cortes, MD: I always talk to my patients about toxicities that are common and inconvenient but not life-threatening or severe. The life-threatening ones may be silent sometimes, but they could be there. Myelosuppression is common to all the TKIs [tyrosine kinase inhibitors], and that's where you need to monitor your patients for neutrophils, platelets, hemoglobin, etc. If they get to be grade 3, then it's usually recommended to stop therapy, monitor the patient closely, and resume therapy when they recover. They usually recover quickly within 2 weeks you can resume at the same dose. If not, then they may require a dose adjustment."

Video

2021 Updates on Ph+ ALL: Chemo+Dasatinib, Dasatinib vs. Imatinib in Pediatric Disease, Hyper-CVAD Combos, Blina+InO/Dasatinib/Ponatinib, InO+Bosutinib, Ponatinib+Venetoclax (VuMedi) - https://www.vumedi.com/channel/soho-italy-1st-school-of-acute-leukemia/tab/videos-498/video/2021-updates-on-ph-all-chemodasatinib-dasatinib-vs-imatinib-in-pediatric-disease-hyper-cvad-combos-b/

Video

Weinberg Describes the Available Options for Patients With GIST (YouTube) - "Benjamin Weinberg,...discusses the overall prognosis of patients with gastrointestinal stromal tumor (GIST)."

Video

Cellular and Targeted Therapies Push the Envelope in Hematologic Malignancies (OncLive) - "In an interview with OncLive during an Institutional Perspectives in Cancer webinar on Leukemia and Lymphoma, Zonder, a professor of hematology-oncology at Barbara Ann Karmanos Cancer Institute, Wayne State University, highlighted the impact of CAR T-cell therapy in lymphoma and multiple myeloma and ongoing research efforts in leukemia....Do you see the use of axi-cel expanding beyond its current indication? The role of CAR T-cell therapy is gradually evolving. Axi-cel has been approved in relapsed diffuse large B-cell lymphoma, but we now have data looking at other types of lymphoma, such as low-grade lymphomas. I believe its role will continue to expand in lymphoma and the implications for which it is approved will grow over time."

Interview